ANI buys some old Merck drugs to challenge Mallinckrodt; Aerie launches glaucoma Phase III;

@FierceBiotech: COMMENTARY: Why would Martin Shkreli hike an old drug price by 5000%? Only a 'moron' would ask. More | Follow @FierceBiotech

@JohnCFierce: One win, one loss in Merck's PhIII double header for C diff. Story | Follow @JohnCFierce

@DamianFierce: Filed under Roche Hubris Watch: Reuters article | Follow @DamianFierce

> ANI Pharmaceuticals ($ANIP) paid Merck ($MRK) $75 million for a pair of approved but little-used drugs, planning to relaunch them and compete with Mallinckrodt Pharmaceuticals' ($MNK) Acthar gel. More

> Aerie Pharmaceuticals ($AERI) has kicked off a Phase III trial of Roclatan, its in-development eye drop for glaucoma and ocular hypertension. News

> Boehringer Ingelheim is teaming up with Germany's BioMed X Innovation Center in hopes of identifying the epigenetic regulators of COPD. Item

Medical Device News

@FierceMedDev: ICYMI: Upstart Establishment gets $20M+ to bring safer breast implants with nanotech, RFID tracking to U.S. Article | Follow @FierceMedDev

@StacyALawrence: ICYMI last week: Google hires top government brain scientist to probe mental illness. Story | Follow @StacyALawrence

@EmilyWFierce: Some light reading on Otsuka and Proteus' antipsychotic with a built-in sensor. Wired story | Follow @EmilyWFierce

> The NBA's studying wearable monitors. Will players soon wear them during games? More

> CMS proposal to restrict coverage of artificial limbs facing pushback from amputees. Article

Pharma News

@FiercePharma: Consumer ranking of fast-food chains' antibiotics in meat calls out FDA, industry for change. FierceAnimalHealth report | Follow @FiercePharma

@EricPFierce: ICYMI from FiercePharmaManufacturing: Ireland pharma biz going to the dogs, so to speak. Nextvet picks up biologics plant there. Item | Follow @EricPFierce

@CarlyHFierce: Watch out, Afinitor. Bristol's 'breakthrough' Opdivo is coming for you. More from FiercePharmaMarketing | Follow @CarlyHFierce

> Hillary Clinton to lay out her plan for cutting drug prices. Article

> Bloomberg: Sanofi, Pfizer mull potential deal for Mexican generics maker Rimsa. More

Animal Health News

> Science think tank calls for global phaseout of antibiotics in agriculture. More

> Merck pioneers injectable vaccine for common pig disease. Item

> VetStem launches trial of drug-free method for preventing hemorrhage in horses. Story

> Consumer ranking of fast-food chains' antibiotics in meat calls out FDA, industry for change. Article

> ViroVet spins out of Aratana with focus on livestock health. Report

Biotech IT News

> Traders pay SEC $30M to settle newswire hacking case. More

> Google lures NIH mental health chief to life sciences team. News

> Harvard connection helps WuXi NextCODE land Chinese hospital contract. Report

> Microsoft lands cloud genomics infrastructure deal with UC Santa Cruz. Article

> Number of clinical trials to use wearables nears 300. Story

Pharma Marketing News

> More followers and more daily tweeting as Big Pharma's Twitter presence grows. Story

> Sanofi, Pfizer said to be among suitors for Mexico's Rimsa. Item

> Janssen's latest Prezcobix effort taps HIV activists to curate patient-story contest. More

> For sale: Orange paint. It might just become your brand's signature. Editor's Corner

> Watch out, Afinitor. Bristol's 'breakthrough' Opdivo is coming for you. Article

Suggested Articles

Outgoing BIO Chair John Maraganore and his successor, Jeremy Levin, reflected on drug pricing, its drivers and its place in the innovation ecosystem.

The study is assessing the effect of the oral AXL inhibitor when given to elderly AML patients in combination with low-intensity chemotherapy.

The proportion of patients who had a greater than 1 g/dL increase in hemoglobin is down on GBT’s prior update but still superior to placebo.